ERBB2 and Langer mesomelic dysplasia: Third, while this analysis includes a more modern cohort of patients, a relatively small number of patients received HER2-directed TKIs, ADCs, and other novel therapies prior to and after the diagnosis of LMD, even after some of these agents were approved.